The parties to the transaction, i.e., GlaxoSmithKline Dungarvan ("GSK") and AstraZeneca Tika ("AZT") are active in Sweden within the field of, inter alia, consumer health. The Swedish Competition Authority ("SCA") divided the sale of pharmaceuticals into the following three markets; personal (...)
